Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with Type 2 diabetes : the onset 3 trial
Saravanan, P. Rodbard, H. Tripathy, D. Velazquez, M. V. Demissie, M. Can Tamer, S. Piletic, M.
Saravanan, P.
Rodbard, H.
Tripathy, D.
Velazquez, M. V.
Demissie, M.
Can Tamer, S.
Piletic, M.
Abstract
Poster abstract P111 in section 'Basic and clinical science posters: new insulins, technology, therapies and treatment' from the Diabetes UK Professional Conference 2017, Manchester Central, Manchester, 8–10 March 2017.
MIDER Authors
Affiliations
University of Warwick; George Eliot Hospital, Nuneaton; Endocrine and Metabolic Consultants, Rockville, Maryland, USA; University of Texas Health Science Center, USA; Audie L. Murphy VA Hospital, San Antonio, Texas, USA; Hospital General Regional 110, Guadalajara, Mexico; Novo Nordisk A/S, Søborg, Denmark; General Hospital, Novo Mesto, Slovenia
Citations
Altmetric:
Date
2017-03-08
Type
Conference Output
Subject
Collections
Citation
Saravanan P, Rodbard H, Tripathy D, Velazquez MV, Demissie M, Can Tamer S, Piletic M. Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with Type 2 diabetes: the onset 3 trial. Diabetic Medicine. 2017 Mar;34(S1):69. doi: 10.1111/dme.14_13304.